<DOC>
	<DOCNO>NCT01080807</DOCNO>
	<brief_summary>The primary objective study determine whether armodafinil treatment effective placebo treatment patient excessive sleepiness associate shift work disorder ( SWD ) measure improve clinical condition late shift , include commute home .</brief_summary>
	<brief_title>Efficacy Tolerability Armodafinil Adults With Excessive Sleepiness Associated With Shift Work Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disorders Excessive Somnolence</mesh_term>
	<mesh_term>Armodafinil</mesh_term>
	<mesh_term>Modafinil</mesh_term>
	<criteria>1 . The patient currently meet criterion Shift Work Disorder ( SWD ) duration least 1 month . 2 . The patient presence excessive sleepiness late shift , include commute home applicable , Clinical Global Impression Severity Illness ( CGIS ) rating 4 screening . 3 . The patient clinically significant difficulty social occupational functioning , Global Assessment Function ( GAF ) score less 70 ( clinician interview ) screening . 4 . The patient Karolinska Sleepiness Scale ( KSS ) score 6 screening ( visit 1 ) confirm baseline ( visit 2 ) . 5 . The patient work least 5 night shift per month , least 3 night consecutive , plan maintain schedule . 6 . The patient work night shift rotate shift include least 6 hour 2200 0800 ( include time period 0400 0800 ) , shifts longer 12 hour duration . 7 . The patient good health , judge investigator . 8 . The patient able complete selfrating scale . 9 . Women childbearing potential ( surgically sterile 2 year postmenopausal ) , must use medically accept method contraception , must continue use 1 method duration study ( 30 day participation study ) . Acceptable method contraception include : abstinence , barrier method spermicide , steroidal contraceptive ( oral , transdermal , implanted , inject ) conjunction barrier method , intrauterine device ( IUD ) . 10 . The patient willing able comply study restriction attend regularly schedule clinic visit specify protocol 1 . The patient mild severe obstructive sleep apnea ( OSA ) define apnea/hypopnea index 5 determine daytime polysomnography ( PSG ) . 2 . The patient medical psychiatric disorder cause clinically significant functional impairment contribute patient 's excessive sleepiness . 3 . The patient currently take medication substance cause clinically significant functional impairment contribute patient 's excessive sleepiness . 4 . The patient clinically significant treat untreated medical condition . 5 . The patient history clinically significant suicidal ideation judgment principal investigator currently suicidal base medical psychiatric history . 6 . The patient know hypersensitivity armodafinil , racemic modafinil , component study drug tablet . 7 . The patient history clinically significant cutaneous drug reaction , history clinically significant hypersensitivity reaction , include multiple allergy drug reaction . 8 . The patient consumes caffeine include coffee , tea and/or caffeine contain beverage food average 600 mg caffeine per day within 7 day baseline visit . 9 . The patient us prescription overthecounter ( OTC ) drug disallow protocol within 30 day baseline visit . 10 . The patient prior armodafinil study . 11 . The patient history alcohol , narcotic , drug abuse . 12 . The patient positive urine drug screen ( UDS ) without medical explanation screen visit . 13 . The patient clinically significant deviation normal physical examination . 14 . The patient pregnant lactate woman . 15 . The patient use investigational drug within 1 month screen visit . 16 . The patient disorder could interfere absorption , distribution , metabolism , excretion investigational product . 17 . The patient need use exclude medication protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>